Pirlindole in the treatment of depression and fibromyalgia syndrome

Clinical Drug Investigation

Volumn 31, Issue 10, 2011, Pages 675-689

  Branco, Jaime C ^a,b   Tomé, Ana Maria ^c,d   Cruz, Manuel R ^e   Filipe, Augusto ^c  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b HOSPITAL EGAS MONIZ   (Portugal)

^c Tecnimede Group   (Portugal)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^e Centro Hospitalar Psiquiatrico de Lisboa   (Portugal)

Author keywords

Antidepressants; Depression; Fibromyalgia; Monoamine oxidase A inhibitors; Pirlindole

Indexed keywords

ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMITRIPTYLINE; DOPAMINE; DULOXETINE; FLUOXETINE; GUANETHIDINE; ISOPRENALINE; MAPROTILINE; METARAMINOL; METHYLDOPA; MILNACIPRAN; MOCLOBEMIDE; NORADRENALIN; PAROXETINE; PIRLINDOLE; PLACEBO; REBOXETINE; RESERPINE; SERTRALINE; VENLAFAXINE;

AGITATION; ANOREXIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONCENTRATION LOSS; DEPRESSION; DIZZINESS; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR FUNCTION; SIDE EFFECT; SKIN DISEASE; SWEATING; TREMOR; VERTIGO; WEAKNESS; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CARBAZOLES; COST OF ILLNESS; DEPRESSION; FIBROMYALGIA; HUMANS; MONOAMINE OXIDASE INHIBITORS;

EID: 80052428708     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11595410-000000000-00000     Document Type: Review

References (69)

1. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (updated edition). CG90. London, UK: The British Psychological Society and the Royal College of Psychiatrists, 2009
2. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008 Apr; 67 (4): 536-41 (Pubitemid 351498437)
3. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010 May; 62 (5): 600-10
4. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007 Sep; 61 (9): 1498-508 (Pubitemid 47228612)
5. Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 2010 May; 26 (4): 284-90
6. Langlieb AM, Guico-Pabia CJ. Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry 2010; 12 (2): e1-14
7. Rivera J, Rejas J, Esteve-Vives J, et al. Resource utilization and health care costs in patients diagnosed with fibromyalgia in Spain. Clin Exp Rheumatol 2009 Sep-Oct; 27 (5 Suppl. 56): S39-45
8. Salaffi F, Sarzi-Puttini P, Girolimetti R, et al. Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. Clin Exp Rheumatol 2009 Sep-Oct; 27 (5 Suppl. 56): S67-74
9. Sicras-Mainar A, Rejas J, Navarro R, et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009; 11 (2): R54
10. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008 Jan; 50 (1): 13-24
11. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum 2008 Jan; 58 (1): 26-35
12. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999 Jan-Feb; 40 (1): 57-63 (Pubitemid 29056581)
13. Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther 2006; 8 (5): 218
14. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, et al. Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum 2009 Jul; 60 (7): 2169-73
15. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003 May-Jun; 72 (3): 115-27 (Pubitemid 36469860)
16. Storosum JG, Elferink AJ, van Zwieten BJ. Schizophrenia: do we really need placebo-controlled studies? Eur Neuropsychopharmacol 1998 Dec; 8 (4): 279-86
17. World Health Organization. Global Health Risks: mortality and burden of disease attributable to selected major risks. Geneva: WHO Press, 2009
18. Eaton WW, Martins SS, Nestadt G, et al. The burden of mental disorders. Epidemiol Rev 2008; 30: 1-14
19. King M, Nazareth I, Levy G, et al. Prevalence of common mental disorders in general practice attendees across Europe. Br J Psychiatry 2008 May; 192 (5): 362-7 (Pubitemid 351692381)
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition-text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000
21. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidencebased guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008 Jun; 22 (4): 343-96 (Pubitemid 351989984)
22. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA): American Psychiatric Association (APA), 2010
23. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71 Suppl. E1: e04
24. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004 Nov 17; 292 (19): 2388-95 (Pubitemid 39491924)
25. Garcia-Campayo J, Magdalena J, Magallon R, et al. A metaanalysis of the efficacy of fibromyalgia treatment according to level of care. Arthritis Res Ther 2008; 10 (4): R81
26. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a metaanalysis. JAMA 2009 Jan 14; 301 (2): 198-209
27. Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008 Sep 15; 59 (9): 1279-98
28. Bruhwyler J, Liegeois JF, Geczy J. Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. Pharmacol Res 1997 Jul; 36 (1): 23-33 (Pubitemid 27458577)
29. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010 Jun; 39 (6): 448-53
30. Martorana PA, Schindler U, Nitz RE. The novel antidepressant pirlindole: a pharmacological profile. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 195-8
31. Silverstone T. Introduction to a new generation of antidepressant drugs: pirlindol. Psicopatologia (Madrid) 1987; 7 (3): 432-6 (Pubitemid 17133175)
32. Martorana PA, Heucke U, Nitz RE. The new antidepressant pirlindole: antagonism of acute overdosage in the mouse.Arzneimittelforschung 1979; 29 (6): 950-2
33. Mashkovsky MD, Andrejeva NI. Pharmacological properties of 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino [3,2,1-j,k]carbazol hydrochloride (pirlindole), a new antidepressant. Arzneimittelforschung 1981; 31 (1): 75-9 (Pubitemid 11174830)
34. Medvedev AE, Shvedov VI, Chulkova TM, et al. The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding. J Neural Transm 1998; 52 Suppl.: 337-42
35. Medvedev AE, Shvedov VI, Chulkova TM, et al. Effects of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase-A and on GABAA receptors. Neurochem Res 1996 Dec; 21 (12): 1521-6
36. Ostrowski J, Theumer J, Gartner W, et al. The pharmacokinetics of pirlindole in man. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 209-17
37. Bruhwyler J, Liegeois JF, Gerardy J, et al. Comparative study of pirlindole, a selective RIMA, and its two enantiomers using biochemical and behavioural techniques. Behav Pharmacol 1998 Dec; 9 (8): 731-7 (Pubitemid 29017625)
38. Pentafarma, Sociedade Teónico-Medicinal, SA (Grupo Tecnimede). Pirlindol, summary of product characteristics. Abrunheira; 2009
39. Bruhwyler J, Monseu MJ, Vandekerckhove K, et al. Pirlindole, a reversible and selective monoamine oxidase A inhibitor: a retrospective evaluation of its clinical antidepressant profile. Eur J Clin Res 1997; 9: 1-21
40. Ehlers T, Ritter M. Placebo-controlled investigation of the effects of pirlindole on sensorimotor performance and subjective condition in comparison to imipramine and under the influence of ethanol. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 245-51
41. Saletu B, Grunberger J. On acute and chronic CNS effects of antidepressants in normals: neurophysiological, behavioral and pharmacokinetic studies with pirlindol. Methods Find Exp Clin Pharmacol 1985 Mar; 7 (3): 137-51 (Pubitemid 15121268)
42. Schwarz JA, Resag K, Kostkina B. Is there a tyramine potentiating effect of pirlindole? In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 233-9
43. Demisch K, Demisch L, Buchholz G, et al. Effect of pirlindole on endocrine parameters in healthy man. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 219-23
44. Leydhecker W. Effect of a single dose of 225mg pirlindole on intraocular pressure and diameter of pupils in 10 patients with eye disease without primary raise in intraocular pressure. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 337-44
45. Buchholz G, Demisch K, Demisch L, et al. Antidepressive efficacy of pirlindole in man. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 329-35
46. Muldner H, Wegehaupt S. Clinical trials with the new antidepressant pirlindole in patients with depression and various psychiatric diseases. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 263-70
47. Walcher W. Pirlindole in depression: an open clinical study. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 253-7
48. Schwarz JA, Scharz H, Kalhammer R. Dosage and efficacy of the antidepressant pirlindole in 15 female in-patients with depressive syndrome. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 271-6
49. Schwarz JA, Neumann H, Kalhammer R. Efficacy and tolerance of pirlindole in 20 male in-patients with psychosis; organic brain dysfunction and accompanying depression. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 277-82
50. Boissl K, Rigler O. Long-term tolerance of pirlindole in patients with chronic schizophrenia and accompanying depressive symptomatology. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 259-62
51. Nahunek K, Rysanek R, Svestka J, et al. Clinical trial of pyrazidol in endogenous depressive states. Activ Nerv Sup (Praha) 1980; 22 (3): 170-1 (Pubitemid 11192617)
52. Zapletalek M, Libiger J, Kasparkova E, et al. Pyrazidole in the treatment of endogenous depression: a controlled study. Cesk Psychiatr 1981; 77 (1): 31-7 (Pubitemid 11074552)
53. De Wilde JE, Geerts S, Van Dorpe J, et al. A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psychiatr Scand 1996 Dec; 94 (6): 404-10 (Pubitemid 27028800)
54. Blaha L. A double-blind comparative study of pirlindole and amitriptyline in thirty depressive patients. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. Vol. 3. Pharmacopsychiatry. New York (NY): Plenum Press, 1983: 303-9
55. Schapperle O, Eckmann F, Immich H. A double blind comparison of pirlindole with amitriptyline and imipramine. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 297-302
56. Saletu B, Grunberger J, Rajna P, et al. Examining pharmaco EEG-based predictions about the antidepressant action of pirlindol by double blind clinical trials. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. NewYork (NY): Plenum Press, 1985: 291-6
57. Lehmann E, Kinzler E, Stuckman A, et al. A double-blind comparative study on the use of 225 mg pirlindole and 150 mg desipramine in the treatment of depressive inpatients. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 321-7
58. PoldingerW. Pirlindole: results of an open clinical study in outpatients and of a double blind study against maprotiline. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 283-9
59. De Wilde J, Mertens C, Van Dorpe J, et al. Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor monoamine oxidase A, and mianserin, in the treatment of depression. Hum Psychopharmacol 1997; 12: 41-6 (Pubitemid 27110293)
60. Tanghe A, Geerts S, Van Dorpe J, et al. Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Acta Psychiatr Scand 1997 Aug; 96 (2): 134-41 (Pubitemid 27345273)
61. Geerts S, Vandekerckhove K, Bruhwyler J, et al. Study report. Pirlindole versus fluoxetine in the treatment of major depression: a controlled double-blind medium-term study. Sintra: Grupo Tecnimede, 1999. (Data on file)
62. Ginsberg F, Joos E, Geczy J, et al. A pilot randomized placebo- controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskelet Pain 1998; 62 (2): 5-17 (Pubitemid 28340371)
63. Macedo A, Leiria E, Filipe A. Pirlindole in the treatment of depression: a meta-analysis. Clin Drug Investig 2011; 31 (1): 61-71
64. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990 Feb; 33 (2): 160-72
65. Derogatis LR. The SCL-90-R Manual: scoring, administration and procedures for the SCL-90-R. Baltimore (MD): Clinical Psychometric Research, 1977
66. Mashkovski MD, Grinev AN, Andreeva NA, et al. Pyrazidol: a new antidepressive preparation. Pharm Chem J 1974; 8 (3): 192-7
67. Rudenko GM. New psychotropic agents: pirazidol and phenazepam. Pharm Chem J 1979; 13 (4): 445-51
68. Ziegler B, Schneider E, Wegehaupt S. Studies of the effects of pirlindole on sleep. In: Pichot P, Berner P, Wolf R, et al., editors. Psychiatry: the state of the art. New York (NY): Plenum Press, 1985: 241-4
69. Fiedler VB, Buchheim S, Nitz RE, et al. Haemodynamic effects of pirlindole, a new tetracyclic antidepressant agent. Arzneimittelforschung 1983; 33 (2): 244-50 (Pubitemid 13184342)